



Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #19-19) 5/21/2019
Aralez Pharmaceuticals Inc (ARLZQ)

Notice has been received that the above Company's Revised Second Amended Joint Liquidating became effective on 5/17/2019. Pursuant to the plan, API Interests shall be extinguished, cancelled and released on the Effective Date, and holders thereof shall not receive any Distribution on any account of such existing API interests. Please consult the company's bankruptcy filings for thorough details.¹

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Operations- 1-866-776-0800.

¹ See e.g., *In re: Aralez Pharmaceuticals US Inc., et al.*, Debtors. Chapter 11 Case No. 18-12425 (MG) (Jointly Administered) Revised Second Amended Joint Liquidating Plan of the Debtors Under Chapter 11 Of the Bankruptcy Code.